Biswas, G <br/><br/>
Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience.  [electronic resource] 

 -  The Journal of the Association of Physicians of India  Jan 2006 
 - 29-33 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0004-5772 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD20--drug effects<br/>Antineoplastic Agents--adverse effects<br/>Disease Progression<br/>Female<br/>Humans<br/>India<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Proto-Oncogene Proteins c-bcl-2--drug effects<br/>Retrospective Studies<br/>Rituximab<br/>Survival Rate